Our proprietary PREDATOR™ protein engineering technology integrates specialized protein design elements to enhance activity, stability and tumor selectivity within a single molecule.
With the PREDATOR™ platform we are now able to:
Design potent immune modulators that remain inactive in the systemic circulation
Achieve excellent exposure in tumors through optimized pharmaceutical properties
Selectively deliver fully-potent immune stimulators upon activation by the tumor micro-environment
We are developing well-validated pro-inflammatory cytokine and costimulatory receptor agonists in a conditionally-activated format to stimulate potent anti-tumor responses without eliciting normal tissue damage, to achieve maximum therapeutic potential.